OT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA).

Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity. Lidorestat improves nerve conduction and reduces the formation of cataracts. Lidorestat can be used to treat complications of chronic diabetes.

Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment of cataracts, ulcerative colitis, meningitis and Kawasaki's disease and Parkinson's disease.

Conduritol A has a hypoglycemic effect, can have an effect on regulating the metabolism of blood lipid, free-radical scavenging, enhancing the antioxidant ability, potentiating immune function; it also can markedly prevent the diabetic rats from getting c

N-Acetylcarnosine acetate (N-Acetyl-L-carnosine acetate), a natural histidine-containing dipeptide, is a source of pharmacological principal L-carnosine. N-Acetylcarnosine is a potent ophthalmic drug in human cataracts

Bendazac-d7 L-lysine is a deuterated compound of Bendazac L-lysine. Bendazac L-lysine has a CAS number of 81919-14-4. Bendazac L-Lysine is an agent introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.

(Z)-KC02 is an ABHD16A inhibitor which targets the enzyme responsible for producing lysophosphatidylserine (lyso-PS), a lipid involved in regulating immune and neurological functions. This compound is linked to the mitigation of neurological disorders, including retinitis pigmentosa and cataracts (PHARC), by depleting lyso-PS in lymphoblasts from affected individuals. Moreover, (Z)-KC02 diminishes lyso-PS levels and lipopolysaccharide-induced cytokine production in macrophages and influences lyso-PS metabolism in vivo [1].

Cotosudil is a ROCK kinase inhibitor with antihypertensive activity and is used to treat or prevent diseases or conditions caused by cataracts, cardiovascular or neurodegenerative diseases or nerve damage.

Zenarestat (CI-1014, FK-366, FR-74366) is an aldose reductase inhibitor being studied as a treatment for diabetic neuropathy and cataracts.

OT-551, a NF-κB inhibitor, is used potentially for the treatment of cataracts and age-related macular degeneration.

BYAKANGELICIN,a main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitor,and is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.

Dityrosine, an oxidation product of protein formed through the intermolecular cross-linking of tyrosyl radicals from the reactive oxygen species (ROS) and tyrosine interaction, is associated with decreased hippocampal expression of NMDA receptor subunits Nr1, Nr2a, and Nr2b when administered intragastrically at 320 µg/kg per day, leading to memory impairments in mice as evidenced by their performance in a novel object recognition test. Additionally, it raises fasting blood glucose levels while reducing plasma insulin levels and the pancreatic expression of insulin synthesis-related genes Ins2, Pdx1, and MafA. Increased dityrosine levels have been positively linked to a range of diseases, including autism spectrum disorder, cataracts, Alzheimer’s disease, Parkinson’s disease, atherosclerosis, and cystic fibrosis.

Bendazac L-lysine (Bendazaco lisina) is an agent introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.

N-Acetylcarnosine (N-Acetyl-L-carnosine) is thought to be able to combat some of the effects of oxidative stress as it has anti-oxidant properties.